Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 28

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
 expense, net$678 $506 $1,305 $959 

Inventories(in millions)June 30,2025December 31, 2024Finished goods$1,681 $1,173 Work-in-process2,113 1,951 Raw materials1,166 1,057 Inventories$4,960 $4,181 

2025 Form 10-Q | 6

Property and Equipment, Net(in millions)June 30,2025December 31, 2024Property and equipment, gross$12,934 $12,267 Accumulated depreciation(7,651)(7,133)Property and equipment, net$5,283 $5,134 Depreciation expense was $186 million for the three months and $367 million for the six months ended June 30, 2025 and $184 million for the three months and $367 million for the six months ended June 30, 2024.

Note 3 Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.

The following table summarizes the impact of the two-class method:Three months endedJune 30,Six months endedJune 30,(in millions, except per share data)2025202420252024Basic EPSNet earnings attributable to AbbVie Inc.$938 $1,370 $2,224 $2,739 Earnings allocated to participating securities10 10 20 20 Earnings available to common shareholders$928 $1,360 $2,204 $2,719 Weighted-average basic shares outstanding1,768 1,768 1,768 1,769 Basic earnings per share attributable to AbbVie Inc.$0.52 $0.77 $1.25 $1.54 Diluted EPSNet earnings attributable to AbbVie Inc.$938 $1,370 $2,224 $2,739 Earnings allocated to participating securities10 10 20 20 Earnings available to common shareholders$928 $1,360 $2,204